Abstract
A 54-year-old housewife was seen in consultation at the Ohio State University Thyroid Clinic because of weight loss. Twelve years previously, she had experienced substantial weight loss and other symptoms that had been attributed to Graves’ disease which was treated with 131I resulting in prompt resolution of her symptoms. She remained well until four months prior to her present consultation when she was hospitalized for pneumonia from which she recovered quickly; nonetheless, since having pneumonia she had lost 25 pounds despite having a good appetite. In addition, she had recently been developing symptoms of easy fatigability, palpitations, nervousness, heat intolerance, muscle weakness, and hair loss.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ingbar SH: Thyrotoxicosis: Classification and manifestations, in Ingbar SH, Braverman LE (eds): Werner’s The Thyroid: A Fundamental and Clinical Text, ed 5. Philadelphia, JB Lippincott Co., 1986, pp 809–810.
de los Santos ET, Mazzaferri EL: Thyrotoxicosis. Results and risks of current therapy. Postgrad Med. 1990 Apr;87(5):277–278,281-286,288,291-294.
Nordyke RA, Gilbert FT, Harada AS: Graves’ disease. Influence of ages on clinical findings. Arch Intern Med. 1988 Mar;148:626–631.
McKenzie JM, Zakarija M: Hyperthyroidism, in: DeGroot LJ (ed): Endocrinology, ed 2. Philadelphia, WB Saunders Co, 1989, pp 846–682.
Mazzaferri EL: The thyroid, Mazzaferri EL (ed): Textbook of Endocrinology ed 3. New York, Medical Examination Publishing, 1986, pp 89–350.
Bahn RS, Garrity JA, Bartley GB, et al: Diagnostic evaluation of Graves’ ophthalmopathy. Endocrinol Metab Clin North Am. 1988;17:527–545.
de los Santos ET, Stanch GH, Mazzaferri EL: Sensitivity, specificity and cost-effectiveness of sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149:526–532.
de los Santos ET, Mazzaferri EL: Thyroid function tests. Guidelines for interpretation in common clinical disorders. Postgrad Med. 1989;85:333–352.
Larsen PR, Alexander NM, Chopra D, et al: Revised nomenclature for tests of thyroid hormone and thyroid related protein in serum. J Clin Endocrinol Metab. 1987;64:1089–1094.
Hay ID, Klee GG: Thyroid dysfunction. Endocrinol Clin North Am. 1988;17:473–509.
de los Santos ET, Mazzaferri EL: Sensitive thyroid stimulating hormone assays: Clinical applications and limitations. Compr Ther. 1988;14(9):26–33.
Zakarija M, McKenzie JM: Pregnancy-associated changes in the thyroid stimulating antibody of Graves’disease and the relationship with neonatal hyperthyroidism. J Clin Endocrinol Metab. 1983;57:1036–1040.
Tamaki H, Amino N, Aozasa M, et al: Universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment. Am J Perinatol. 1988 Apr;5:152–158.
Orgiazzi J, Madec AM, Genetet N, et al: Immunological parameters in Graves’ disease: Are they useful for indication and monitoring of antithyroid drug treatment? Horm Res. 1987;26:131–136.
Refetoff S: Thyroid function tests and effects of drugs on thyroid function, in DeGroot LJ (ed): Endocrinology, ed 2. Philadelphia, WB Saunders Co, 1989 pp 590–639.
Cooper DS: Antithyroid drugs. Engl J Med. 1984;311:1353–1362.
Fenzi G, Hashizume K, Roudebush CP, et al: Changes in thyroid stimulating immunoglobulins during antithyroid therapy. J Clin Endocrinol Metab 1979;48:572–576.
Teng CS, Yeung RTT: Change in thyroid-stimulating antibody activity in Graves’disease treated with anti-thyroid drugs and its relationship to relapse: A prospective study. J Clin Endocrinol Metab. 1980;50:144–147.
Hanson JS: Propylthiouracil and hepatitis. Two cases and a review of literature. Arch Intern Med. 1984;144:994–996.
Limaye A, Ruffolo PR: Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol. 1987;82:152–154.
Leclere J: Anti-thyroid drugs-A rational treatment for Graves’ disease? Horm. Res. 1987;26:125–130.
Mazzaferri EL, Reynolds JC, Young RL, et al: Propranolol as primary therapy for thyrotoxicosis. Result of a long-term prospective study. Arch Intern Med. 1976;136:50–56.
Feely J, Peden N: Use of beta-adrenoceptor blocking drugs in hyperthyroidism. Drugs. 1984;27:425–446.
Kamel N, Upsala AR, Kologlu S, et al: Sodium ipodate in the treatment of toxic diffuse goiter. Short-term or long-term effects on thyrotoxicosis. Rom J Med. 1988;26:99–105.
Roti E, Robuschi G, Manfredi A, et al: Comparative effect of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves’ disease. Clin Endocrinol. 1985;22:489–496.
Orgiazzi J: Management of Graves’ hyperthyroidism. Endocrinol Clin North Am. 1987;16:365–389.
Goolden AWG, Stewart JSW: Long-term results from graded low-dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol. 1986;24:217–222.
Graham GD, Burman KD: Radioiodine treatment of Graves’disease. An assessment of its possible risks. Ann Intern Med. 1986;105:900–905.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
de los Santos, E.T., Mazzaferri, E.L. (1991). Diagnosis and Management of Thyrotoxicosis. In: Bowen, J.M., Mazzaferri, E.L. (eds) Contemporary Internal Medicine. Contemporary Internal Medicine, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9823-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9823-4_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9825-8
Online ISBN: 978-1-4757-9823-4
eBook Packages: Springer Book Archive